Navigation Links
Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference
Date:7/10/2009

, while helping to allow for coverage for those without medical insurance," stated Dr. William E. Carlson, Chief Medical Officer of Connectyx Technologies Holdings Group, Inc.

"We are pleased with the results Connectyx has achieved over the first six months of this year. The company increased revenues by 45% and reduced expenses by 20% in the second quarter of 2009 as compared to the same period of 2008. This is the second consecutive quarter in which the Company has substantially decreased expenses while growing revenues," said Ronn Schuman, Connectyx President and CEO.

An audio version of the Connectyx nationwide teleconference will be available today at www.connectyx.com.

About Connectyx Technologies Holdings Group, Inc.

Connectyx Technologies provides products in the healthcare market, which includes its Personal Health Record, MedFlash. The MedFlash product is an easy to use Personal Health and Lifestyle Record & Portal that is USB flash drive enabled. MedFlash contains an emergency flash drive with a Web portal and 24/7 emergency call center access, which contains the owner's complete medical and key related information. Stored information on the MedFlash can be accessed on any computer, securely with complete privacy for the members. For more information, please visit www.connectyx.com and www.medflash.com

Safe Harbor Act: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the im
'/>"/>

SOURCE Connectyx Technologies Holdings Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Connectyx Technologies Holdings Group, Inc. to Host Nationwide Teleconference Today, July 9, 2009; Company Will Discuss Recent Developments, New Partnerships and Initiatives for MedFlash EPHR, and Second Quarter Results
2. Connectyx Technologies Holdings Group, Inc. Increases Revenues by 45% and Reduces Expenses by 20% for the Second Quarter of 2009 Versus Second Quarter 2008
3. Connectyx Technologies Holdings Group, Inc. Signs an Agreement with Healthy Directions, LLC, Americas Largest Publisher of Alternative and Complementary Health Newsletters to Distribute its MedFlash EPHR
4. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
5. Connectyx Technologies Holdings Group, Inc. to Host Nationwide Teleconference on July 9, 2009
6. Connectyx Technologies Signs Distributor to Serve the Vast South East Asia Market with its MedFlash Electronic Personal Health Record
7. Connectyx Partners with I-DENTI-FIED, Inc., to Add RFID Transponder Technology as Part of its MedFlash Personal Health Record
8. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
9. Connectyx to Hold National Press Event at National Press Club Tomorrow in Washington D.C. to Announce Launch of MedSync PHR Software
10. Connectyx to Hold National Press Event at National Press Club on May 13th in Washington D.C. to Announce Launch of MedSync PHR Software
11. Pistachio Industry Looks Toward a Promising 2009 Crop Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... University of California, San Diego School of Medicine report ... peppers produces chronic activation of a receptor on ... that ultimately reduces the risk of colorectal tumors. , ... issue of The Journal of Clinical Investigation . ... originally discovered in sensory neurons, where it acts as ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... and work in manufacturing jobs may have significantly less endurance than ... study of 32 people -- half were obese, half were of ... that were about 60 percent longer. Obesity also was associated ... Being older -- 50 to 65 years of age ...
(Date:8/1/2014)... In a first-of-its-kind study, researchers at University Hospitals Rainbow ... infants may be at greater risk for death on ... emergencies on flights worldwide between January 2010 and June ... children under the age of 2. , The ... the rare event of an in-flight pediatric fatality onboard ...
(Date:8/1/2014)... As AndroGel lawsuits and testosterone lawsuits ... Johnson, Jr. has been appointed as co-lead counsel to ... medications. Since the Fall of 2013, Ron and his ... to investigate and prosecute the claims of men who ... as a result of taking testosterone. As a result ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... PHILADELPHIA Scientists believe they have identified a role for ... from UVB radiation, a known risk factor for non-melanoma skin ... , a journal of the American Association for Cancer Research. ... at the University of Chicago, found that laboratory mice with ...
... School of Public Health (HSPH) has been awarded a ... Gates Foundation to test the effectiveness of an innovative ... outcomes of mothers and infants in 120 hospitals in ... Organization (WHO) and HSPH. Atul Gawande, associate professor in ...
... 2011 Adding hormone therapy to radiation therapy has ... survival for men with intermediate- and high-risk prostate cancer. ... men with pre-existing heart conditions, even if they have ... published online in advance of print in the ...
... for returning veterans may include addictions, injury and the ... a University of Houston joint study funded by the ... to address these issues through the use of virtual ... Work (GCSW) joins Baylor College of Medicine and the ...
... People who abused methamphetamine or other amphetamine-like stimulants were ... did not, in a new study from the Centre ... examined almost 300,000 hospital records from California covering 16 ... disorders had a 76 per cent higher risk of ...
... ROCKVILLE, MD, USA/BEIJING, CHINA, July 26, 2011 Aeras and ... of a memorandum of understanding for the organizations to pursue ... potentially other parts of the world. The partnership ... development of TB vaccines. TB is a major public ...
Cached Medicine News:Health News:Harvard School of Public Health receives $14.1 million to test childbirth checklist 2Health News:Harvard School of Public Health receives $14.1 million to test childbirth checklist 3Health News:Hormone therapy may be hazardous for men with heart conditions 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Increased risk of Parkinson's disease in methamphetamine users, CAMH study finds 2Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
(Date:8/1/2014)... Aug. 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... pivotal Phase 3 study evaluating ISIS-SMN Rx in ... genetic cause of infant mortality. Isis plans to dose ... few weeks, at which time Isis will earn an ... Idec. The Phase 3 study, ENDEAR, is the first ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3
... stapler is a full-feature skin stapler with ... RH has improved visibility over existing fixed-head ... mechanism for easier staple placement., ,This ... use instrument designed to deliver rectangular, stainless ...
... linear stapler with LACTOMER™ 9-1 ... is a copolymer of glycolide ... Suture™ ROTICULATOR 55 POLY™ single ... use in abdominal, gynecologic, pediatric ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
Medicine Products: